A Longitudinal Study of Effect of Copaxone in RRMS Over 24 Months
NCT01695434 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60
Last updated 2013-03-25
Summary
To explore whether treatment with glatiramer acetate (GA) may decrease iron deposition in subcortical deep GM, as detected by SWI-filtered phase imaging, in patients with RRMS over 24 months and compared to a reference population of healthy controls.
Conditions
Interventions
- OTHER
-
MRI
All subjects will undergo a MRI.
Sponsors & Collaborators
-
University at Buffalo
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2012-06-30
- Primary Completion
- 2013-02-28
- Completion
- 2013-02-28
Countries
- United States
Study Locations
More Related Trials
-
A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS
NCT04121221 ·Status: COMPLETED ·Phase: PHASE3
-
An fMRI Study of Treatment Optimization Comparing Two Disease Modifying Therapies Used to Treat Relapsing Remitting Multiple Sclerosis
NCT00398528 ·Status: TERMINATED
-
Safety and Tolerability of Glatiramer Acetate
NCT01874145 ·Status: COMPLETED ·Phase: PHASE3
-
A Prospective Study of Spasticity in Individuals With Multiple Sclerosis
NCT01111435 ·Status: UNKNOWN
-
Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS)
NCT00001248 ·Status: RECRUITING
-
Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
NCT01464905 ·Status: UNKNOWN ·Phase: PHASE3
-
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
NCT00882999 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of Tysabri in Patients With Relapsing-Remitting Multiple Sclerosis: A Follow-up Magnetization Transfer Imaging (MTI) Study
NCT00937677 ·Status: COMPLETED
-
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
NCT01067521 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA).
NCT00337779 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Monthly Long-acting IM Injection of 25mg or 40 mg GA Depot in Subjects With PPMS
NCT03362294 ·Status: TERMINATED ·Phase: PHASE2
-
Effects of Gilenya (Fingolimod) on Thalamus Pathology and Cognitive Impairment in Patients With Relapsing Forms of Multiple Sclerosis
NCT02021162 ·Status: COMPLETED
-
Evaluate Early Glatiramer Acetate Treatment in Delaying Conversion to Clinically Definite Multiple Sclerosis of Subjects Presenting With Clinically Isolated Syndrome
NCT00666224 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Disease Activity With Long Term Natalizumab Treatment
NCT02677077 ·Status: COMPLETED
-
Assessment Study of Steroid Effect in Relapsing Multiple Sclerosis Subjects Treated With Glatiramer Acetate
NCT00203047 ·Status: TERMINATED ·Phase: PHASE4
-
Comparison of Brain Atrophy Rates, Cognition, and Patient-Reported Outcomes in MS Patients Using Long-term Fingolimod and Glatiramer Acetate
NCT02307877 ·Status: COMPLETED
-
Glatiramer Acetate for Multiple Sclerosis With Autoimmune Comorbidities
NCT01456416 ·Status: COMPLETED
-
Study of the Safety and Efficacy of MLN1202 in Patients in Multiple Sclerosis
NCT01199640 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of GTR in Comparison to Copaxone®
NCT01489254 ·Status: COMPLETED ·Phase: PHASE3
-
An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
NCT01578785 ·Status: TERMINATED ·Phase: PHASE3
-
Comparison of Rituximab Induction Therapy Followed by Glatiramer Acetate
NCT01569451 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS)
NCT04079088 ·Status: WITHDRAWN ·Phase: PHASE2
-
Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients
NCT01167426 ·Status: COMPLETED ·Phase: PHASE3
-
Safety, Tolerability and Efficacy of Monthly Long-acting IM Injection of 80 or 40 mg GA Depot in Subjects With RRMS
NCT02212886 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety and Efficacy Study of Copaxone Administered in Combination With N-Acetylcysteine
NCT00203099 ·Status: COMPLETED ·Phase: PHASE2